ArticleGenes & development2020
Context-dependent functional compensation between Ythdf m
Article in Genes & development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 250 citations in OpenAlex.
- DDX17 and viral infection.Virulence · 2026Review
- Hypothalamus Participates in Peripheral Sympathetic Hyperactivity After Acute Brain Injury by RegulatingMedComm · 2026Article
- NPoultry science · 2026Review
- mNature reviews. Neuroscience · 2026Review
- The m⁶A reader YTHDF2 regulates mRNA transport and axon outgrowth in developing neurons.Nature communications · 2026Article
- Ythdf2 loss in microglia aggravates ischemic retinopathy by increasing microglia activation and microvascular anomalies.Journal of advanced research · 2026Article
- Regulatory elements on chromatin-associated RNA 15 years beyond RNA epigenetics.Nature chemical biology · 2026Review
- The crucial role of m6A methylation modification in nasopharyngeal carcinoma.Discover oncology · 2026Review
- RNA methylation in cardiovascular remodeling: Molecular mechanisms, biomarkers, and therapeutic strategies.Molecular biology reports · 2026Review
- mThe EMBO journal · 2026Article
- IGF2BP3 promotes progression of head and neck cancers through the circHECTD2/hsa_miR_4310/7157-5p/Smad2 signaling axis in an mMolecular cancer · 2026Article
- Comprehensive Profiling of NAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Emerging role of RNA modification reader YTHDF2 in hematopoiesis, immunity, and cancer.MedScience · 2026Review
- Single-nucleotide m⁶A mapping uncovers redundant YTHDF function in planarian progenitor fate selection.The EMBO journal · 2026Article
- NNature reviews. Cancer · 2026Review
- The regulatory role of mFrontiers in cell and developmental biology · 2026Review
- RNA methylation in autoimmune rheumatic diseases: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
- ALKBH5 deficiency suppresses hepatocarcinogenesis in mice via mActa pharmacologica Sinica · 2026Article
- IGF2BP3 recognizes mThe EMBO journal · 2026Article
- Marked for Success: How RNA mCellular and molecular gastroenterology and hepatology · 2026Review
110 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 2 institutions in 2 countries.
Funding
Abstract
The N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.